During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).

At ECO 2026, findings from a post-hoc indirect treatment comparison of Wegovy versus Foundayo, oral GLP-1RAs approved in the US for chronic weight management.

Kyowa Kirin has received approval from the FDA for a dosing update to the Crysvita prescribing information, introducing a new option for adults with XLH.

Hundreds of biopharma leaders say Dr Richard Pazdur has the necessary qualities to lead the FDA amid a crisis of confidence.

Arna Pharma and Slate Run Pharmaceuticals have completed a JV to form a company focusing on branded products and 505(b)(2) medicines.

OTXL’s COO, Beth White, notes that the CGT marketplace could revitalise programmes that would otherwise have been indefinitely put on ice.

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

Pfizer has received EC approval to expand the Hympavzi indication to treat haemophilia A or B with inhibitors in patients aged 12 years and over.

AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form of stomach cancer, after a ...

Streeting’s resignation comes in the wake of the Labour party’s poor performance in the local elections, held on 7 May.

At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss was presented.

Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale.